Information  X 
Enter a valid email address

Company Name matching 'Bavarian Nordic A/S'

Date
Time Source
Company
Announcement
30 Apr 2020 5:46 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces a New Order for JYNNEOS Smallpox Vaccine from the U.S. Government Potentially Worth USD 200 Million
30 Mar 2020 12:00 pm GNW   Bavarian Nordic A/S Bavarian Nordic Updates its Financial Calendar for 2020
24 Feb 2020 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Present at Cowen and Company’s 40th Annual Health Care Conference
20 Feb 2020 6:46 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Annual Report 2019
31 Dec 2019 11:14 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash Preparedness
17 Dec 2019 6:36 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces the Sale of Priority Review Voucher
13 Dec 2019 9:26 am GNW   Bavarian Nordic A/S Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline
15 Nov 2019 1:00 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Present at Jefferies 2019 London Healthcare Conference
13 Nov 2019 6:30 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer
07 Nov 2019 11:03 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen
  6:44 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Nine Months of 2019
21 Oct 2019 7:59 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline
24 Sep 2019 6:45 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
15 Aug 2019 6:51 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces First Half 2019 Results
25 Jun 2019 7:46 am GNW   Bavarian Nordic A/S Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense Programs
19 Jun 2019 6:08 pm GNW   Bavarian Nordic A/S Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine
05 Jun 2019 8:11 pm GNW   Bavarian Nordic A/S Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
22 May 2019 6:51 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Three Months of 2019
14 May 2019 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host First Quarter 2019 Results Conference Call
28 Mar 2019 7:00 am GNW   Bavarian Nordic A/S Bavarian Nordic A/S – Notice Convening Ordinary General Meeting
21 Mar 2019 6:47 am GNW   [email protected] Bavarian Nordic Announces Annual Report 2018
21 Feb 2019 6:33 pm GNW   [email protected] Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
25 Jan 2019 10:58 am GNW   [email protected] Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
18 Jan 2019 6:15 am GNW   [email protected] Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
21 Dec 2018 8:28 pm GNW   [email protected] Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
09 Nov 2018 6:48 am GNW   [email protected] Bavarian Nordic Announces Interim Results for the First Nine Months of 2018
02 Nov 2018 4:30 pm GNW   [email protected] Bavarian Nordic to Host Third Quarter 2018 Results Conference Call
  1:55 pm GNW   [email protected] Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers
01 Nov 2018 1:33 pm GNW   [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma
19 Sep 2018 6:30 am GNW   [email protected] Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox Cases
18 Sep 2018 6:50 pm GNW   [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
21 Aug 2018 6:45 am GNW   [email protected] Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise
16 Aug 2018 6:57 am GNW   [email protected] Bavarian Nordic Announces First Half 2018 Results
09 Aug 2018 4:56 pm GNW   [email protected] Bavarian Nordic Granted EUR 30 Million Loan from The European Investment Bank
08 Aug 2018 4:30 pm GNW   [email protected] Bavarian Nordic to Host First Half 2018 Results Conference Call
  1:07 pm GNW   [email protected] Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
11 Jul 2018 11:01 am GNW   [email protected] Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
01 Jun 2018 4:30 pm GNW   [email protected] Bavarian Nordic to Present at Jefferies 2018 Healthcare Conference in New York City
31 May 2018 7:00 am GNW   [email protected] Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer
24 May 2018 6:42 am GNW   [email protected] Bavarian Nordic Announces Interim Results for the First Three Months of 2018
16 May 2018 10:00 pm GNW   [email protected] Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
  4:30 pm GNW   [email protected] Bavarian Nordic to Host First Quarter 2018 Results Conference Call
02 May 2018 2:34 pm GNW   [email protected] Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma
17 Apr 2018 4:52 pm GNW   [email protected] Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 2018
27 Mar 2018 6:20 pm GNW   [email protected] Bavarian Nordic to Present at Needham & Company's 17th Annual Healthcare Conference in New York City
26 Mar 2018 12:48 pm GNW   [email protected] Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
16 Mar 2018 12:54 pm GNW   [email protected] Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
12 Mar 2018 6:40 am GNW   [email protected] Bavarian Nordic Announces Annual Report 2017
08 Mar 2018 1:59 pm GNW   [email protected] Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
07 Mar 2018 4:30 pm GNW   [email protected] Bavarian Nordic to Host Full Year 2017 Results Conference Call
06 Mar 2018 1:33 pm GNW   [email protected] Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
26 Feb 2018 9:39 am GNW   [email protected] Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
06 Feb 2018 5:22 pm GNW   [email protected] Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
31 Jan 2018 4:04 pm GNW   [email protected] Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen
19 Jan 2018 6:00 am GNW   [email protected] Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
21 Nov 2017 6:05 pm GNW   [email protected] Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
09 Nov 2017 6:30 am GNW   [email protected] Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
08 Nov 2017 6:51 am GNW   [email protected] Bavarian Nordic Announces Interim Results for the First Nine Months of 2017
27 Sep 2017 9:18 pm GNW   [email protected] Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government
21 Sep 2017 9:13 am GNW   [email protected] Bavarian Nordic Provides Update on its Universal RSV Vaccine


Company Announcements Archive »


a d v e r t i s e m e n t